

DTaP-IPV Vaccine

DTaP-IPV Vaccines	Recommended Age	Booster Schedule
Kinrix™ <i>(GlaxoSmithKline)</i> Quadracel™ <i>(Sanofi Pasteur)</i>	4 – 6 years (Booster dose only)	0.5 mL at least 6 months after the 4 th dose of DTaP and 6 months after the previous dose of IPV



DTaP-IPV Vaccine Recommendations

General Recommendations:

- Both DTaP-IPV vaccines **are not** approved for the primary series of DTaP and/or IPV in children 4 through 6 years of age.
- A single dose of **Kinrix** is licensed only for the fifth dose in the DTaP series and fourth dose in the IPV series in children whose DTaP vaccine doses have been with Infanrix and/or Pediarix for the first three doses and Infanrix for the fourth dose.
- A single dose of **Quadracel** is licensed for use as the fifth dose of DTaP and fourth or fifth dose of IPV in children who received DTaP-IPV-Hib (Pentacel) and/or DTaP (Daptacel) vaccine for the first 4 doses.
- Either vaccine may be used when any component of the combination is indicated, and if the other components are not contraindicated for the booster dose at 4-6 years of age.

Administration:

- Whenever possible, it is recommended that the same DTaP vaccine should be used for all doses in the series.
- If a provider does not know or have available the DTaP vaccine product previously administered, vaccine administration should not be deferred and either DTaP-IPV vaccine may be administered.
- If either DTaP vaccine is inadvertently administered before age 4 years (i.e. at 2 months, 4 months, 6 months) for an earlier dose of the DTaP and/or IPV series and if minimum interval requirements have been met, the dose may be counted as valid for the DTaP and/or IPV series and does not need to be repeated.
- Note that the final dose in the IPV series must be administered at age ≥ 4 years regardless of the number of previous doses, and with a minimum interval of 6 months from the previous dose. Therefore, a dose of DTaP-IPV vaccine administered before the fourth birthday can't be counted as a valid final dose of IPV.
- DTaP:** a fifth dose of DTaP-containing vaccine is not needed if the fourth dose was given on or after the fourth birthday.
- IPV:** A fourth dose of IPV-containing vaccine is not needed if the third IPV dose was given on or after the fourth birthday and was given at least 6 months after the previous dose.

Adverse Reactions

- Injection site: pain, redness, swelling, increase in arm circumference.
- Systemic: drowsiness, fever, loss of appetite.

Contraindications

- Hypersensitivity (anaphylaxis reaction after a previous dose of any diphtheria toxoid, tetanus toxoid, pertussis or poliovirus-containing vaccine).
- Encephalopathy (coma, decreased level of consciousness, prolonged seizures).
- Progressive neurologic disorder (infantile spasms, uncontrolled epilepsy, progressive encephalopathy).

Precautions

- Guillain-Barre Syndrome occurring within 6 weeks of receipt of a prior vaccine containing tetanus toxoid.
- Adverse events following prior pertussis vaccination.
- Children at risk for seizures.
- Temperature of 105° within 48 hours not due to another identifiable cause.
- Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours.
- Seizures with or without fever occurring within 3 days.

IP-B71-DIPV-V2 (12/9/15)